Applied Therapeutics Announces Presentations Outlining the Design and Rationale for the ARISE-HF Pivotal Study of AT-001 for Treatment of Diabetic Cardiomyopathy at the 16th Annual Global Cardiovascular Clinical Trialist’s Forum (CVCT)

NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced poster and oral presentations at the 16th Annual Global Cardiovascular Clinical Trialist’s Forum (CVCT) in Washington, D.C. (Embassy of France, December 5-7, 2019) outlining the design and rational for the ARISE-HF study. ARISE-HF is a Phase 3 pivotal study examining effects of AT-001, a novel, potent and selective aldose reductase inhibitor (ARI), on functional capacity (as measured by peak V02) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of progression.

Oral Presentation

Title: AT-001: A Next Generation Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy (DbCM)
Date and Time: Thursday, December 5, 2019, 5:30-7:00pm ET
Session: Are Ongoing Early Trials Designed to Optimally Transition to Phase III?
Presenter: Dr. Francesca Lawson MD, FAHA; Applied Therapeutics

Poster Presentaiton

Title: The ARISE-HF Study – Development of AT-001 for the Treatment of Diabetic Cardiomyopathy: Rationale and Study Design
Date and Time: The poster will be available for viewing from Dec 5 through Dec 7th
Presenter: James L. Januzzi MD;  Massachusetts General Hospital, Boston MA

Both the presentation and poster will be available on the Applied Therapeutics website following the sessions.

About Diabetic Cardiomyopathy
Diabetic Cardiomyopathy (DbCM) is a rapidly progressing degenerative disorder of the heart in patients with both type 1 and type 2 diabetes. There are no approved therapies for this fatal condition, which affects 17 – 24 percent of people with diabetes, or approximately 77 million patients worldwide. Hyperglycemia, a symptom that characterizes diabetes, triggers the enzyme Aldose Reductase to convert excess glucose into sorbitol and fructose, both of which can lead to cell death in the heart muscle. When this happens, the heart fibroses, or “hardens,” such that the organ is unable to circulate blood through the body effectively. Approximately 25 percent of patients with DbCM progress to overt heart failure or death within 1.5 years of diagnosis.